Quick Answer
Marker Therapeutics, Inc. reported Total Revenue of $213.2 thousand for fiscal year 2019.
Marker Therapeutics, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | — | — | — | — | — | — |
| Net Income | -$12.16M -13.3% |
-$10.73M -30.3% |
-$8.24M +72.5% |
-$29.93M +28.5% |
-$41.88M -45.9% |
-$28.71M -34.0% |
| Diluted EPS | -$0.79 +33.6% |
-$1.19 -26.6% |
-$0.94 +73.7% |
-$3.58 +34.6% |
-$5.47 -796.7% |
-$0.61 |
| Total Assets | $19.07M -13.4% |
$22.02M +28.6% |
$17.13M -50.2% |
$34.42M -49.5% |
$68.14M +49.4% |
$45.61M -1.6% |
| Cash and Equivalents | $16.07M -16.3% |
$19.19M +27.0% |
$15.11M +28.3% |
$11.78M -72.2% |
$42.35M +98.3% |
$21.35M -51.4% |
| Stockholders Equity | $16.80M -9.5% |
$18.56M +32.1% |
$14.05M -28.3% |
$19.60M -55.4% |
$43.99M +60.9% |
$27.34M -38.0% |
| R&D Expense | $11.80M -12.4% |
$13.47M +29.3% |
$10.42M -13.0% |
$11.97M -56.9% |
$27.79M +47.2% |
$18.88M +47.9% |
| Operating Income | -$12.89M -15.9% |
-$11.12M +23.7% |
-$14.58M +26.3% |
-$19.79M +49.9% |
-$39.48M -36.7% |
-$28.89M -28.2% |
| Shares Outstanding | 16.70M +56.1% |
10.70M +20.2% |
8.90M +6.0% |
8.40M +1.2% |
8.30M -83.6% |
50.70M +10.9% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2019 | $0.00 | — | — |
| Net Income | September 30, 2025 | -$2.00M | +13.4% | +50.2% |
| Diluted EPS | September 30, 2025 | -$0.12 | +53.8% | +58.6% |
| Total Assets | September 30, 2025 | $21.73M | +99.2% | +47.2% |
| Cash and Equivalents | September 30, 2025 | $17.59M | +95.5% | +68.1% |
| Stockholders Equity | September 30, 2025 | $18.39M | +146.8% | +75.3% |
| R&D Expense | September 30, 2025 | $2.35M | -32.4% | -43.8% |
| Operating Income | September 30, 2025 | -$2.14M | +11.0% | +49.9% |
| Shares Outstanding | September 30, 2025 | 16.70M | +87.6% | +47.8% |
- Marker Therapeutics, Inc. reported Total Revenue of $213.2 thousand for fiscal year 2019.
- Marker Therapeutics, Inc. showed an increase of +3.5% in Total Revenue compared to the prior fiscal year.
- Marker Therapeutics, Inc. reported Net Income of -$12.16 million for fiscal year 2025.
- Marker Therapeutics, Inc. showed a decrease of -13.3% in Net Income compared to the prior fiscal year.
- Marker Therapeutics, Inc. reported Diluted EPS of $0.79 per share (loss) for fiscal year 2025.
- Marker Therapeutics, Inc. showed an increase of +33.6% in Diluted EPS compared to the prior fiscal year.
- Marker Therapeutics, Inc. reported Total Assets of $19.07 million for fiscal year 2025.
- Marker Therapeutics, Inc. showed a decrease of -13.4% in Total Assets compared to the prior fiscal year.
- Marker Therapeutics, Inc. reported Cash and Equivalents of $16.07 million for fiscal year 2025.
- Marker Therapeutics, Inc. showed a decrease of -16.3% in Cash and Equivalents compared to the prior fiscal year.
- Marker Therapeutics, Inc. reported Stockholders Equity of $16.80 million for fiscal year 2025.
- Marker Therapeutics, Inc. showed a decrease of -9.5% in Stockholders Equity compared to the prior fiscal year.
- Marker Therapeutics, Inc. reported R&D Expense of $11.80 million for fiscal year 2025.
- Marker Therapeutics, Inc. showed a decrease of -12.4% in R&D Expense compared to the prior fiscal year.
- Marker Therapeutics, Inc. reported Operating Income of -$12.89 million for fiscal year 2025.
- Marker Therapeutics, Inc. showed a decrease of -15.9% in Operating Income compared to the prior fiscal year.
- Marker Therapeutics, Inc. reported Shares Outstanding of 16.70 million shares for fiscal year 2025.
- Marker Therapeutics, Inc. showed an increase of +56.1% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: